Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Income from Continuing Operations: 2011-2025

Historic Income from Continuing Operations for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$35.6 million.

  • Abeona Therapeutics' Income from Continuing Operations fell 17.47% to -$35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.1 million, marking a year-over-year increase of 4.84%. This contributed to the annual value of -$68.4 million for FY2024, which is 43.88% down from last year.
  • As of Q3 2025, Abeona Therapeutics' Income from Continuing Operations stood at -$35.6 million, which was down 195.60% from -$12.0 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Income from Continuing Operations peaked at -$8.2 million during Q2 2022, and registered a low of -$46.7 million during Q4 2021.
  • For the 3-year period, Abeona Therapeutics' Income from Continuing Operations averaged around -$19.2 million, with its median value being -$15.3 million (2024).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first soared by 71.90% in 2022, then plummeted by 196.31% in 2024.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Income from Continuing Operations stood at -$46.7 million in 2021, then soared by 71.90% to -$13.1 million in 2022, then declined by 1.56% to -$13.3 million in 2023, then plummeted by 33.31% to -$17.8 million in 2024, then fell by 17.47% to -$35.6 million in 2025.
  • Its last three reported values are -$35.6 million in Q3 2025, -$12.0 million for Q2 2025, and -$20.7 million during Q1 2025.